On May 30th of this year, the Food and Drug Administration (FDA) approved a new treatment for moderately to severely active ulcerative colitis.  Tofacitinib, which is made by Pfizer Labs, was previously approved in 2012 for rheumatoid arthritis and in 2017 for psoriatic arthritis. The F...

Each May, Clinical Trials Day is observed to raise awareness of clinical trials and honor research professionals for their commitment and contributions to public health and medical progress. Without clinical trials, we wouldn't have medications available to treat IBD. That's why patient enrollment i...

Clinical trials play a key role in the development and approval of new treatment options for IBD patients. In order to understand patient perceptions and improve recruitment, the Crohn's & Colitis Foundation conducted in-person focus groups over a four-month period in 2016, the results of which ...

Scientists from Dana-Farber Cancer Institute at Harvard Medical School recently reported that a specific type of bacteria that reside in the gut can enable development and dissemination of colorectal cancer.  This type of bacteria, Fusobacterium, was previously shown to be associated with IB...

Each of us encounters defining moments in our lives. Moments that fundamentally shape who we are, moments that reveal our true selves. I’m convinced that our deepest selves are never fully unmasked until we are faced with moments that rattle us to our core. Moments that challenge us to make a life-a...

March is Women’s History Month. The Crohn’s & Colitis Foundation would like to take this opportunity to put the spotlight on some of the fearless women leaders committed to making a difference for IBD patients. For this edition, Cecile Norris, Senior Research Manager at the Foundation, interview...

In recent years, it has been increasingly recognized that the microbes which inhabit the intestinal tract, termed microbiota, have a profound impact on IBD. These microbes are essential to human health, but can become a liability during inflammatory gut disorders. Targeting these microbes via novel ...